Respiratory Syncytial Virus treatment market to surpass $2.3 bn by 2024

download24667

(Photo Courtesy: www.tes.com)

The global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9 percent, says research and consulting firm GlobalData.

According to the company's latest report, this robust growth, which will occur across the seven Major Markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by multiple new product launches in the currently sparse RSV arena.

Dr Christopher J Pace, GlobalData's Director of Infectious Diseases, states that Synagis (palivizumab) is the only licensed product indicated for the prevention of RSV in infants at a high risk of severe infection, and there are no prophylactic agents approved for adults.

Dr Pace explains, "Despite Synagis being effective in many patients, its short half-life and prohibitively high cost limit its utility.

"However, the anticipated launches of novel prophylactic monoclonal antibodies (mAbs) led by MedImmune's MEDI8897 and Regeneron's REGN2222, have provided hope for more cost-effective alternatives to Synagis. GlobalData expects these pipeline agents will be important players in the RSV space across the 7MM by 2024."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X